Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3167260 | 0.94 | KDM4E (0.49) | KDM4ERECQLMAPTPKM | |
| SCHEMBL1866194 | 0.94 | KDM4E (0.49) | KDM4ERECQLMAPTPKM | |
| SCHEMBL28556579 | 0.94 | KDM4E (0.49) | KDM4ERECQLMAPTPKM | |
| SCHEMBL919416 | 0.89 | KCNA3 (0.44) | KDM4ERECQLMAPTKCNA3ALDH1A1 | |
| SCHEMBL919131 | 0.89 | KCNA3 (0.39) | KDM4ERECQLMAPTKCNA3ACACB | |
| SCHEMBL10785918 | 0.88 | KCNA3 (0.43) | KDM4ERECQLMAPTPKMKCNA3 | |
| SCHEMBL7425025 | 0.88 | CYP3A4 (0.42) | KDM4ERECQLMAPT | |
| SCHEMBL921802 | 0.87 | KCNA3 (0.43) | KDM4EKCNA3TSHRMAOA | |
| SCHEMBL921536 | 0.87 | KCNA3 (0.43) | KDM4EKCNA3TSHRMAOA | |
| SCHEMBL920036 | 0.87 | KCNA3 (0.43) | KDM4EKCNA3TSHRMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116910-A1 | Heterocycles as WIP1 Inhibitors | PMV PHARMACEUTICALS, INC. | 2024-04-11 | — | — | US | claimed |
| EP-4330247-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | Nanjing Immunophage Biotech Co., Ltd (CN) | 2024-03-06 | — | — | EP | claimed |
| WO-2022228496-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) | 2022-11-03 | — | — | WO | claimed |
| EP-3740493-B1 | INHIBTEURS DE L'INDOLEAMINE 2,3-DIOXYGÉNASE ET/OU DU TRYPTOPHANE DIOXYGÉNASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-12-01 | — | — | EP | claimed |
| WO-2021078120-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-04-29 | — | — | WO | claimed |
| US-10968198-B2 | Biaryltriazole inhibitors of macrophage migration inhibitory factor | YALE UNIVERSITY (US) | 2021-04-06 | — | — | US | claimed |
| US-20200405696-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-31 | — | — | US | claimed |
| EP-3740493-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | Idorsia Pharmaceuticals Ltd (CH) | 2020-11-25 | — | — | EP | claimed |
| EP-3267794-B1 | BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | UNIV YALE (US) | 2020-09-09 | — | — | EP | claimed |
| CN-111601810-A | Inhibitors of indoleamine 2, 3-dioxygenase and/or tryptophan 2, 3-dioxygenase | 爱杜西亚药品有限公司 | 2020-08-28 | — | — | CN | claimed |
| CN-1143950-A | Nitroxy group-containing benzylamine derivatives and their use for treating cardiovascular diseases, as well as increased intra-ocular pressure | BYK NEDERLAND BV (NL) | 1997-02-26 | — | — | CN | claimed |
| EP-0740649-A1 | NITROXY GROUP-CONTAINING BENZYLAMINE DERIVATIVES AND THEIR USE FOR TREATING CARDIOVASCULAR DISEASES, AS WELL AS INCREASED INTRA-OCULAR PRESSURE | Byk Nederland BV (NL) | 1996-11-06 | — | — | EP | claimed |
| CN-1132756-A | Antiviral ethers of aspartate protease substrate isosteres | CIBA GEIGY AG (CH) | 1996-10-09 | — | — | CN | claimed |
| EP-0708085-A2 | Antiviral ethers of aspartate protease substrate isosteres | CIBA-GEIGY AG (CH) | 1996-04-24 | — | — | EP | claimed |
| WO-1995019952-A1 | NITROXY GROUP-CONTAINING BENZYLAMINE DERIVATIVES AND THEIR USE FOR TREATING CARDIOVASCULAR DISEASES, AS WELL AS INCREASED INTRA-OCULAR PRESSURE | BYK NEDERLAND BV (NL) | 1995-07-27 | — | — | WO | claimed |
| EP-0193227-B1 | PROCESS FOR THE PREPARATION OF ARYLGLYCIDYL ETHERS AND 3-SUBSTITUTED 1-ALKYLAMINO-2-PROPANOLS | GIST-BROCADES N.V. (NL) | 1990-04-11 | — | — | EP | claimed |
| US-4818766-A | ANTIARRHYTHMIA AGENTS, HYPOTENSIVE AGENTS, TREATMENT OF ANGINA | CIBA-GEIGY CORPORATION (US) | 1989-04-04 | — | — | US | claimed |
| EP-0254682-A1 | Phenoxyaliphatylphenylenoxyalkylesters and -amides | CIBA-GEIGY AG (CH) | 1988-01-27 | — | — | EP | claimed |
| CN-86102227-A | The preparation method of 1-alkylamino-2-propyl alcohol that arylolycidyl ethers and 3-replace | — | 1987-02-04 | — | — | CN | claimed |
| EP-0193227-A1 | Process for the preparation of arylglycidyl ethers and 3-substituted 1-alkylamino-2-propanols | GIST-BROCADES N.V. (NL) | 1986-09-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968198-B2 | Biaryltriazole inhibitors of macrophage migration inhibitory factor | MIF, MMP12, CSF1R | KDM4E 3312/4885RECQL 4644/4885MAPT 4521/4885 |
| US-20200405696-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDO2, TDO2, IDO1 | KDM4E 1391/4885RECQL 1374/4885MAPT 3139/4885 |
| US-20240116910-A1 | Heterocycles as WIP1 Inhibitors | WAPL, WHR1, G3BP1 | KDM4E 1647/4885RECQL 579/4885MAPT 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.